Book contents
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Acknowledgments
- 1 Introduction
- Part I Innovation and industry evolution
- 2 Pharmaceutical innovation as a process of creative destruction
- 3 The evolution of pharmaceutical innovation
- 4 Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals
- 5 Innovation and industry evolution: a comment
- Part II Firm growth and market structure
- Part III Policy implications
- Index
- References
5 - Innovation and industry evolution: a comment
Published online by Cambridge University Press: 22 September 2009
Book contents
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Acknowledgments
- 1 Introduction
- Part I Innovation and industry evolution
- 2 Pharmaceutical innovation as a process of creative destruction
- 3 The evolution of pharmaceutical innovation
- 4 Firm and regional determinants in innovation models: evidence from biotechnology and traditional chemicals
- 5 Innovation and industry evolution: a comment
- Part II Firm growth and market structure
- Part III Policy implications
- Index
- References
Summary
Joseph Schumpeter long ago provided those seeking an understanding of modern capitalist economic growth with a dynamic model. The central engine that made capitalism run, Schumpeter explained, was the entrepreneur, the innovator, the unusual businessman who combined capital, labor, and natural resources to develop a new product, a new service, a new source of raw materials or a new form of business organization (Schumpeter, 1934; Stolper, 1994). Schumpeter rounded out his theory in 1942, when he published Capitalism, Socialism, and Democracy, which added a political and social superstructure to the original, unchanged model of economic growth.
At that time, most governments were so fully engaged with World War II and, later, with the serious problems of rebuilding their economies that they paid no attention to Schumpeter's ideas, and even the economics profession was largely oblivious to his concepts. In the postwar years Keynesian analysis was on the throne, securely established, it appeared, by the remarkable recovery of the American economy from the Great Depression of the 1930s. Forced to use the powerful tool of large-scale deficit financing, the United States had emerged from the war as the most powerful and successful economy in the world (Abramovitz and David, 2000; Maddison, 1995). The American economy was so successful that there seemed to be little need to reflect on the quality of the nation's entrepreneurship during what came to be called “the American century” (Stein, 1969; Collins, 1981; Zelizer, 1998; Galambos and Pratt, 1988).
- Type
- Chapter
- Information
- Knowledge Accumulation and Industry EvolutionThe Case of Pharma-Biotech, pp. 145 - 160Publisher: Cambridge University PressPrint publication year: 2006
References
Abramovitz, M., and P. A. David (2000), “American macroeconomic growth in the era of knowledge-based progress: the long-run perspective,” in and (eds.), The Cambridge Economic History of the United States, Vol. III, The Twentieth Century, Cambridge University Press, New York, 66–84.Google Scholar
, and (2001), “The dynamics of technological innovation: the case of the pharmaceutical industry,” Research Policy, 30, 535–88.CrossRefGoogle Scholar
Arora, A., and A. Gambardella (1998), “Evolution of industry structure in the chemical industry,” in , , and (eds.), Chemicals and Long-Term Economic Growth: Insights from the Chemical Industry, Wiley, New York, 379–413.Google Scholar
, and (2004), “Recent trends in the research on national innovation systems,” Journal of Evolutionary Economics, 14, 197–210.CrossRefGoogle Scholar
, , , , and (2001), “Innovation and corporate growth in the evolution of the drug industry,” International Journal of Industrial Organization, 19 (7), 1161–87.CrossRefGoogle Scholar
, , , , and (2003), Impact of Public–Private Partnerships Addressing Access to Pharmaceuticals in Low-Income Countries: Uganda Pilot Study, Global Forum for Health Research, Geneva.Google Scholar
. (1962), Strategy and Structure: Chapters in the History of the Industrial Enterprise, MIT Press, Cambridge, MA.Google Scholar
. (1977), The Visible Hand: The Managerial Revolution in American Business, Harvard University Press, Cambridge, MA.Google Scholar
. (1990), Scale and Scope: The Dynamics of Industrial Capitalism, Harvard University Press, Cambridge, MA.Google Scholar
. (2001), Inventing the Electronic Century: The Epic Story of the Consumer Electronics and Computer Industries, Free Press, New York.Google Scholar
. (2005), Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries, Harvard Business School Press, Boston.CrossRefGoogle Scholar
(1997), The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail, Harvard Business School Press, Boston.Google Scholar
, and (1998), “Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery,” Journal of Industrial Economics, 46 (2), 157–81.CrossRefGoogle Scholar
, and (1994), Built to Last: Successful Habits of Visionary Companies, Harper Business, New York.Google Scholar
(1981), The Business Response to Keynes, 1929–1964, Columbia University Press, New York.Google Scholar
, , , and (1995), “Research and development costs for new drugs by therapeutic category,” PharmacoEconomics, 7 (2), 152–69.CrossRefGoogle ScholarPubMed
, and (2004), “The African comprehensive HIV/AIDS partnerships – a new role for multinational corporations in global health policy,” Yale Journal of Health Policy, Law, and Ethics, 4 (1), 147–55.Google ScholarPubMed
, and (1994), “An introduction to evolutionary theories in economics,” Journal of Evolutionary Economics, 4, 153–72.CrossRefGoogle Scholar
(1996), “Public research and private development: patents and technology transfer in government-sponsored research,” Virginia Law Review, 82 (8), 1663–727.CrossRefGoogle Scholar
(2003), “Schumpeter and the revival of evolutionary economics: an appraisal of the literature,” Journal of Evolutionary Economics, 13, 125–59.CrossRefGoogle Scholar
Galambos, L. (2000), “The U.S. corporate economy in the twentieth century,” in and (eds.), The Cambridge Economic History of the United States, Vol. III, The Twentieth Century, Cambridge University Press, New York, 927–67.Google Scholar
, and (1988), The Rise of the Corporate Commonwealth: United States Business and Public Policy in the Twentieth Century, Basic Books, New York.Google Scholar
, and (1998), “Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation,” Business History Review, 72 (Summer), 250–78.CrossRefGoogle Scholar
(1995), Science and Innovation: The US Pharmaceutical Industry During the 1980s, Cambridge University Press, Cambridge.CrossRefGoogle Scholar
Gambardella, A., L. Orsenigo, and F. Pammolli (2000), “Benchmarking the competitiveness of the European pharmaceutical industry,” European Commission, Brussels.
, and (2000), “The determinants of pharmaceutical research and development expenditures,” Journal of Evolutionary Economics, 10, 201–15.CrossRefGoogle Scholar
, and (1993), Reengineering the Corporation: A Manifesto for Business Revolution, Harper Business, New York.Google Scholar
(2003), Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development, Edward Elgar, Cheltenham.CrossRefGoogle Scholar
Henderson, R. M., L. Orsenigo, and G. Pisano (1999), “The pharmaceutical industry and the revolution in molecular biology: exploring the interactions between scientific, institutional, and organizational change,” in and (eds.), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge University Press,Cambridge, 267–311.CrossRefGoogle Scholar
(1998), The Foundations of Evolutionary Economics, 1890–1973, Edward Elgar, Northhampton, MA.Google Scholar
, and (2001), “Political Regimes, Technological Regimes and Innovation in the Evolution of the Pharmaceutical Industry in the USA and in Europe,” paper presented at Conference on Evolutionary Economics, Johns Hopkins University, Baltimore, 30–31 March.Google Scholar
, , and (1999), Pharmaceutical Innovation: Revolutionizing Human Health, Chemical Heritage Press, Philadelphia.Google Scholar
(1995), Monitoring the World Economy, 1820–1992, Development Centre, Organisation for Economic Co-operation and Development, Paris.Google Scholar
Ministry of State President, National AIDS Coordinating Agency (2003), Status of the 2002 National Response to the UNGASS Declaration of Commitment on HIV/AIDS, Country Report, Government of Botswana, Gaborone.
, and (eds.) (1999), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge University Press, Cambridge.CrossRefGoogle Scholar
(2003), Knowledge and Competitive Advantage: The Coevolution of Firms, Technology, and National Institutions, Cambridge University Press, New York.CrossRefGoogle Scholar
(1993), National Innovation Systems: A Comparative Analysis, Oxford University Press, New York.Google Scholar
(ed.)(1995), “Recent evolutionary theorizing about economic change,” Journal of Economic Literature, 33, 48–90.Google Scholar
, and (1982), An Evolutionary Theory of Economic Change, Harvard University Press, Cambridge, MA.Google Scholar
, , and (2001), “Technological change and network dynamics: lessons from the pharmaceutical industry,” Research Policy, 30, 485–508.CrossRefGoogle Scholar
, and . (1982), In Search of Excellence: Lessons from America's Best-Run Companies, Harper, New York.Google Scholar
, and (1984), The Second Industrial Divide: Possibilities for Prosperity, Basic Books, New York.Google Scholar
(1934; Galaxy edn., 1961), The Theory of Economic Development: An Inquiry into Profits, Capital, Credit, Interest, and the Business Cycle, Oxford University Press, New York.Google Scholar
(1994), Joseph Alois Schumpeter: The Public Life of a Private Man, Princeton University Press, Princeton, NJ.Google Scholar
, and (1997), The Leadership Engine: How Winning Companies Build Leaders at Every Level, Harper Collins, New York.Google Scholar
UNAIDS (2003), Accelerating Action Against AIDS in Africa, Joint United Nations Programme on HIV/AIDS, Geneva.
, and (2004), Medicine, Science and Merck, Cambridge University Press, Cambridge.CrossRefGoogle Scholar
(1998), Taxing America: Wilbur D. Mills, Congress, and the State, 1945–1975, Cambridge University Press, New York.Google Scholar
, and (1995), Virtuous Circles of Productivity: Star Bioscientists and the Institutional Transformation of Industry, Working Paper no. 5342, National Bureau of Economic Research, Cambridge, MA.CrossRefGoogle Scholar
- 3
- Cited by